Tivic Schedules Follow-Up BARDA Meeting on Entolimod for Acute Radiation Syndrome

Reuters
Feb 18
Tivic Schedules Follow-Up BARDA Meeting on Entolimod for Acute Radiation Syndrome

Tivic Health Systems Inc. will attend a follow-up meeting with the Biomedical Advanced Research and Development Authority (BARDA) on March 10, 2026, to continue discussions on clinical data and potential U.S. government funding and stockpiling of its TLR5 agonist Entolimod for Acute Radiation Syndrome. Event-related link: https://www.accessnewswire.com/

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202602180915ACCESSWRNAPR_____1138397) on February 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10